Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase 3 open-label study of BIVV009 in primary cold agglutinin disease
2017-003538-10Phase 3Completed
- Sponsor
- Sanofi
- Start
- Oct 2017
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 3, open-label, single-arm trial of sutimlimab in cold agglutinin disease (CAD) and autoimmune haemolytic anaemia (AIHA), sponsored by Sanofi. Primary endpoint: Responder rate at end of treatment (Week 26). Started Oct 2017; status: completed.
02
Drugs
sutimlimab
03
Conditions
cold agglutinin disease (CAD)autoimmune haemolytic anaemia (AIHA)
Beyond the preview
Go deeper on 2017-003538-10.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2017-003538-10.